<DOC>
	<DOCNO>NCT02110472</DOCNO>
	<brief_summary>The Presbia Flexivue Microlens corneal inlay .</brief_summary>
	<brief_title>Investigation Presbia Flexivue Microlens™</brief_title>
	<detailed_description>Presbyopia multifactorial physiological age mechanism lead progressive functional loss near vision . In addition use reading glass presbyopia , wide variety procedure investigated ophthalmologist correct refractive error . Cornea laser surgery multifocal pattern monovision approach develop include LASIK , PresbyLASIK , photorefractive keratectomy ( PRK ) , laser epithelial keratomileusis ( LASEK ) , thin-flap femto-LASIK sub-Bowman 's keratomileusis ( SBK ) . Conductive keratoplasty ( CK ) , clear lens extraction cataract surgery use multifocal , pseudo-accommodative intraocular lens ( IOLs ) monovision monofocal IOLs also techniques use treatment presbyopia . Corneal laser surgery CK minimally invasive method , provoke irreversible change corneal anatomy , whereas scleral surgery clear lens extraction invasive technique . The necessity develop minimally invasive , reversible , safe surgical technique easy learn curve patient 45 60 year , lead development refractive intracorneal lens ( inlay ) ( AcuFocus , Inc. KAMRA™ , ReVision Optics® PresbyLens® , Presbia Flexivue Microlens™ ) place inside corneal stroma . These inlay refractive lenses central zone free refractive power peripheral zone standard positive refractive power . These inlay insert inside corneal stroma non-dominant eye , generally offer two different focal point , one far vision different near vision respectively . The pocket cornea create use laser ( detail provide later protocol ) . The Presbia Flexivue Microlens intend improve near vision decrease dependence reading glass presbyopic adult tolerant monovision ( evaluated participation monovision tolerance trial ( 5 7 day minimum ) ) , require read add +1.50 D +3.50 D , MRSE +1.00 D 0.75 D 0.75 D refractive cylinder , stable MRSE within 0.50 D past 12 month . Objective : The primary objective study evaluate safety effectiveness Presbia Flexivue Microlens™ ( hereinafter refer `` Microlens '' ) implant presbyopes improvement near vision . Investigational Plan : This prospective , non-randomized , unmasked , multicenter clinical investigation . A total 412 subject 11 investigational site United States undergo insertion Microlens non-dominant eye , follow 36 month postoperative ( assume estimate 10 % per year lose follow-up ) . Each site contribute target minimum 20 treated subject , 25 % total subject treat study . Data minimum 300 subject 24 month data submit part Premarket Approval ; subject follow 36 month postoperative . Subjects outside United States enrol study .</detailed_description>
	<mesh_term>Presbyopia</mesh_term>
	<criteria>Subjects must emmetropes presbyopia , ≥ 45 year ≤ 60 year age time eligibility visit . Subjects must need read add +1.50 D +3.50 D. Subjects must uncorrected near visual acuity 20/50 worse . Subjects must near visual acuity correctable 20/20 good eye . Subjects must distance visual acuity correctable 20/25 good eye . Subjects must preoperative spherical equivalent +1.00 D 0.75 D 0.75 D refractive cylinder determine cycloplegic refraction eye . Subjects must photopic pupil size &gt; 1.6 mm eye implant . Subjects nondominant eye determine use one method identify test ocular dominance . Subjects complete monovision tolerance trial ( minimum 5 7 day ) . Subjects report completely satisfied vision monovision tolerance trial . Subjects report experience debilitate significant visual symptom halo , glare , double vision , etc . monovision tolerance trial . Subjects difference ≥ 1.00 D spherical equivalent manifest refraction spherical equivalent cycloplegic refraction . Subject prefer near work distance &lt; 35 cm &gt; 45 cm . Subjects corneal thickness &lt; 500 micron eye implant . Subjects clinically significant anterior segment pathology , include cataract , either eye . Subjects residual , recurrent , active ocular uncontrolled eyelid disease progressive corneal abnormality ( include endothelial dystrophy , guttata central cornea , etc . ) eye treat . Subjects keratoconus ( keratoconus suspect ) , amblyopia , recurrent erosion syndrome corneal dystrophy eye treat . Subjects history chronic dry eye control therapy superficial punctuate keratitis ( SPK ) grade &gt; II ( i.e. , great mild ) base Oxford Grading Scale eye treat . Subjects abnormal corneal mire topography map eye treat . Subjects require canthotomy generate corneal tunnel eye treat . Subjects progressive retinal pathology reasonable chance cause reduction BCVA preoperative eye treat . Subjects undergone previous intraocular corneal surgery include cataract refractive surgery ( e.g. , LASIK surgery ) either eye . Subjects use ophthalmic medication ( ) artificial tear treatment ocular pathology . Subjects history autoimmune disease , connective tissue disease , clinically significant atopic syndrome . Subjects history herpes zoster herpes simplex keratitis . Subjects history steroidresponsive rise intraocular pressure ( IOP ) , preoperative IOP &gt; 21 mmHg glaucoma . Subjects distort , nonreactive , decentered pupil . Subjects take medication control diabetes . Subjects chronic systemic topical corticosteroid immunosuppressive therapy may affect wound healing , immunocompromised subject ( use intranasal steroid seasonal allergy acceptable ) . Subjects use systemic medication ( e.g. , amiodarone ) medication significant ocular side effect . Subjects pregnant , consider become pregnant time study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Emmetropic presbyope</keyword>
	<keyword>Presbyopic</keyword>
</DOC>